Chifa Zhang - Genscript Biotech Executive
| GNNSF Stock | USD 1.26 0.11 8.03% |
Executive
Mr. Zhang Chifa is Department head industry synthetic biology product segment of the company. Since January 2014 and is primarily responsible for management of the research and development center and the industrial synthetic biology product segment of our Group. Mr. Zhang joined our Group in June 2005. Mr. Zhang was the manager of the gene unit from June 2005 to July 2009 and vice president of operations covering some of the departments of the life sciences research service segment and the life sciences research catalog product segment of our Group from August 2009 to January 2014. Prior to joining our Group, Mr. Zhang worked as the laboratory technician at Daye Special Steel Co., Ltd. from October 1996 to September 1999. He worked as the manager of sequencing unit at Shanghai Boya Biotechnology Co., Ltd. from October 1999 to May 2003 and the production manager at Shanghai Connaught Biotechnology Co., Ltd. June 2003 to March 2005. He graduated from a Diploma in Chemical Process at Huangshi Technical College in June 1995. since 2014.
| Age | 48 |
| Tenure | 10 years |
| Phone | 86 25 5889 7288 |
| Web | https://www.genscript.com |
Genscript Biotech Management Efficiency
The company has return on total asset (ROA) of (0.1165) % which means that it has lost $0.1165 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of (0.5574) %, meaning that it generated substantial loss on money invested by shareholders. Genscript Biotech's management efficiency ratios could be used to measure how well Genscript Biotech manages its routine affairs as well as how well it operates its assets and liabilities.Similar Executives
| Showing other executives | EXECUTIVE Age | ||
| PharmD Rasbach | Zentalis Pharmaceuticals Llc | 44 | |
| Wes Trotter | Kronos Bio | N/A | |
| MPH MD | Ovid Therapeutics | N/A | |
| Shannon Campbell | Merus BV | 58 | |
| Harold Waitz | Lineage Cell Therapeutics | 82 | |
| Charles Lin | Kronos Bio | 39 | |
| Charbel PharmD | Inhibrx | N/A | |
| Rami Skaliter | Lineage Cell Therapeutics | 66 | |
| Moses Makunje | Nuvation Bio | 45 | |
| Philippe Sauvage | Nuvation Bio | 47 | |
| Yung MD | Keros Therapeutics | 48 | |
| Stacy Rollinger | NextCure | N/A | |
| Srikanth MD | Connect Biopharma Holdings | N/A | |
| Adrian MD | Zentalis Pharmaceuticals Llc | N/A | |
| Sourav Kundu | NextCure | 63 | |
| John Soglia | Nuvalent | N/A | |
| Andrew MD | Merus BV | 58 | |
| Lora Pike | Ovid Therapeutics | N/A | |
| Bonne MBA | Inhibrx | 47 | |
| Jeff Cole | Cadrenal Therapeutics, Common | N/A | |
| Josep Garcia | Inhibrx | N/A | |
Management Performance
| Return On Equity | -0.56 | |||
| Return On Asset | -0.12 |
Genscript Biotech Leadership Team
Elected by the shareholders, the Genscript Biotech's board of directors comprises two types of representatives: Genscript Biotech inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Genscript. The board's role is to monitor Genscript Biotech's management team and ensure that shareholders' interests are well served. Genscript Biotech's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Genscript Biotech's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Shiniu Wei, Chief Officer | ||
| Li Zhu, Vice President - Strategy | ||
| Brian Min, CEO Bus | ||
| Zhenyu Liu, Chief Officer | ||
| Jiange Meng, Vice President - Finance, Executive Director | ||
| Weihui Shao, Chief Officer | ||
| Chifa Zhang, Department head - industry synthetic biology product segment | ||
| ACIS ACS, Company Sec | ||
| Ye MS, Pres CoFounder | ||
| ChuanChu Chou, Department head - Preclinical Drug Development Service Business Segment |
Genscript Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right pink sheet is not an easy task. Is Genscript Biotech a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.56 | |||
| Return On Asset | -0.12 | |||
| Profit Margin | (0.66) % | |||
| Operating Margin | (0.64) % | |||
| Current Valuation | 5.11 B | |||
| Shares Outstanding | 2.12 B | |||
| Shares Owned By Insiders | 38.31 % | |||
| Shares Owned By Institutions | 24.68 % | |||
| Price To Earning | 200.00 X | |||
| Price To Book | 6.65 X |
Currently Active Assets on Macroaxis
Other Information on Investing in Genscript Pink Sheet
Genscript Biotech financial ratios help investors to determine whether Genscript Pink Sheet is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Genscript with respect to the benefits of owning Genscript Biotech security.